Brief: Sino Biopharmaceutical Announces Collaboration With GSK For Respiratory Therapies In China
08/07/2026 05:08
BRIEF-Sino Biopharmaceutical Announces Collaboration With GSK For Respiratory Therapies In China July 8 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:
SBP GROUP DEEPENS EXCLUSIVE STRATEGIC COLLABORATION WITH GSK FOR RESPIRATORY THERAPIES IN CHINA
SBP GROUP OBTAINS CHINA COMMERCIALISATION RIGHTS FOR GSK'S TRELEGY ELLIPTA AND ANORO ELLIPTA
SBP GROUP TO IMPORT, DISTRIBUTE, AND SELL GSK RESPIRATORY PRODUCTS IN CHINA
CO WILL BE RESPONSIBLE FOR IMPORTATION, DISTRIBUTION, OTHERS FOR THESE PRODUCTS IN MAINLAND CHINA
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit